Anixa Biosciences, Inc. (ANIX)
3.095
-0.04
(-1.12%)
USD |
NASDAQ |
Sep 03, 12:49
Anixa Biosciences Research and Development Expense (TTM) : 4.557M for April 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| April 30, 2026 | 4.557M |
| January 31, 2026 | 4.621M |
| October 31, 2025 | 5.071M |
| July 31, 2025 | 5.405M |
| April 30, 2025 | 6.275M |
| January 31, 2025 | 6.599M |
| October 31, 2024 | 6.396M |
| July 31, 2024 | 6.535M |
| April 30, 2024 | 5.698M |
| January 31, 2024 | 5.05M |
| October 31, 2023 | 4.769M |
| July 31, 2023 | 4.839M |
| April 30, 2023 | 5.196M |
| January 31, 2023 | 5.933M |
| October 31, 2022 | 6.703M |
| July 31, 2022 | 7.191M |
| April 30, 2022 | 7.913M |
| January 31, 2022 | 7.20M |
| October 31, 2021 | 6.190M |
| July 31, 2021 | 4.424M |
| April 30, 2021 | 3.512M |
| January 31, 2021 | 3.718M |
| October 31, 2020 | 4.381M |
| July 31, 2020 | 4.830M |
| April 30, 2020 | 4.662M |
| Date | Value |
|---|---|
| January 31, 2020 | 4.702M |
| October 31, 2019 | 5.459M |
| July 31, 2019 | 7.035M |
| April 30, 2019 | 8.892M |
| January 31, 2019 | 8.282M |
| October 31, 2018 | 6.813M |
| July 31, 2018 | 4.732M |
| April 30, 2018 | 2.153M |
| January 31, 2018 | 1.924M |
| October 31, 2017 | 1.598M |
| July 31, 2017 | |
| April 30, 2017 | |
| January 31, 2017 | |
| October 31, 2016 | |
| July 31, 2016 | |
| April 30, 2016 | |
| January 31, 2016 | |
| October 31, 2015 | |
| July 31, 2015 | |
| April 30, 2015 | |
| January 31, 2015 | |
| October 31, 2014 | |
| July 31, 2014 | |
| April 30, 2014 | |
| January 31, 2014 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Oncolytics Biotech, Inc. | 13.11M |
| Sangamo Therapeutics, Inc. | 113.79M |
| Sarepta Therapeutics, Inc. | 783.60M |
| Vicapsys Life Sciences, Inc. | 0.0043M |